Gilead Sues Merck Saying New Drug Won’t Infringe Patents
This article is for subscribers only.
Gilead Sciences Inc., the world’s largest maker of HIV medicines, sued Merck & Co. seeking a court order that the experimental hepatitis C drug sofosbuvir won’t infringe patents.
Merck, which sold $502 million of its Victrelis hepatitis C drug last year, contacted Gilead this month requesting it license two patents Merck says are related to sofosbuvir, Gilead’s attorneys said a complaint filed yesterday in federal court in San Francisco.